Cover Page
Cover Page | 12 Months Ended |
Dec. 31, 2022 | |
Cover [Abstract] | |
Document Type | DEF 14A |
Entity Registrant Name | SILK ROAD MEDICAL, INC. |
Entity Central Index Key | 0001397702 |
Amendment Flag | false |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) | 12 Months Ended | ||
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Pay vs Performance Disclosure [Line Items] | |||
Pay vs Performance [Table Text Block] | Value of Initial Fixed $100 Investment Based On: Year Summary Compensation Table Total for PEO (1) ($) Compensation Actually Paid to PEO (1)(3) ($) Average Summary Compensation Table Total for Non-PEO Named Executive Officers (2) ($) Average Compensation Actually Paid to Non-PEO Named Executive Officers (2)(3) ($) Total Shareholder Return (4) ($) Peer Group Total Shareholder Return (4) ($) Net Loss (5) ($) Revenue (6) ($) 2022 15,277,073 22,207,540 5,333,659 6,659,604 131 124 ( 55,010,000 ) 138,638,000 2021 3,315,913 ( 1,634,263 ) 2,301,706 ( 61,260 ) 106 153 ( 49,811,000 ) 101,475,000 2020 2,157,780 11,624,424 2,203,657 4,396,738 156 123 ( 47,365,000 ) 75,227,000 _________________ (1) Our PEO for each of 2022, 2021 and 2020 was Ms. Rogers . (2) Our non-PEO Named Executive Officers for 2022 were Mr. Buchanan, Mr. Davis, Mr. Klemz (effective August 15, 2022) and Mr. Ruedy, and for 2021 and 2020 were Mr. Buchanan, Mr. Davis and Mr. Ruedy. (3) The amounts reported as compensation actually paid was computed in accordance with the Pay versus Performance rules under Item 402(v) of Regulation S-K, as described in more detail below. The dollar amounts do not reflect the actual amount of compensation earned or paid to our PEO or non-PEO Named Executive Officers during the applicable year. (4) Total shareholder return is calculated by assuming that a $100 investment was made at the close of trading on December 31, 2019 and reinvesting all dividends until the last day of each reported fiscal year. The total shareholder return of our peer group is based on the NASDAQ US Benchmark Medical Equipment Index, as used in the Company’s performance graph in our annual report. (5) The dollar amounts reported are the Company’s net loss reflected in the Company’s audited financial statements. (6) Our company-selected measure is Revenue , which is a GAAP measure. The dollar amounts reported are reflected in our audited financial statements. | ||
PEO Total Compensation Amount | $ 15,277,073 | $ 3,315,913 | $ 2,157,780 |
PEO Actually Paid Compensation Amount | 22,207,540 | (1,634,263) | 11,624,424 |
Non-PEO NEO Average Total Compensation Amount | 5,333,659 | 2,301,706 | 2,203,657 |
Non-PEO NEO Average Compensation Actually Paid Amount | 6,659,604 | (61,260) | 4,396,738 |
Total Shareholder Return Amount | 131 | 106 | 156 |
Peer Group Total Shareholder Return Amount | 124 | 153 | 123 |
Net Income (Loss) | $ (55,010,000) | $ (49,811,000) | $ (47,365,000) |
Company Selected Measure Amount | 138,638,000 | 101,475,000 | 75,227,000 |
Company Selected Measure Name | Revenue | ||
PEO Name | Ms. Rogers | ||
Adjustment To PEO Compensation, Footnote [Text Block] | 2022 2021 2020 Compensation Actually Paid Calculation Reconciliation PEO Amount ($) Average Non-PEO Named Executive Officers Amount ($) PEO Amount ($) Average Non-PEO Named Executive Officers Amount ($) PEO Amount ($) Average Non-PEO Named Executive Officers Amount ($) Summary Compensation Table Total 15,277,073 5,333,659 3,315,913 2,301,706 2,157,780 2,203,657 Deduction for "Stock Awards" and "Option Awards" amounts reported in the Summary Compensation Table ( 14,110,692 ) ( 4,677,208 ) ( 2,328,629 ) ( 1,629,315 ) ( 1,660,655 ) ( 1,603,546 ) Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year 1,129,846 161,455 213,631 88,365 473,269 169,781 Year End Fair Value of Equity Awards Granted During the Year That are Outstanding and Unvested at Fiscal Year End 18,889,848 5,447,237 1,574,220 668,705 3,778,600 1,806,424 Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards 1,076,522 388,483 ( 2,816,101 ) ( 898,695 ) 5,648,095 1,584,081 Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year ( 55,057 ) 5,978 ( 1,593,297 ) ( 592,025 ) 1,227,335 236,341 Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year — — — — — — Compensation Actually Paid 22,207,540 6,659,604 ( 1,634,263 ) ( 61,260 ) 11,624,424 4,396,738 | ||
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | 2022 2021 2020 Compensation Actually Paid Calculation Reconciliation PEO Amount ($) Average Non-PEO Named Executive Officers Amount ($) PEO Amount ($) Average Non-PEO Named Executive Officers Amount ($) PEO Amount ($) Average Non-PEO Named Executive Officers Amount ($) Summary Compensation Table Total 15,277,073 5,333,659 3,315,913 2,301,706 2,157,780 2,203,657 Deduction for "Stock Awards" and "Option Awards" amounts reported in the Summary Compensation Table ( 14,110,692 ) ( 4,677,208 ) ( 2,328,629 ) ( 1,629,315 ) ( 1,660,655 ) ( 1,603,546 ) Fair Value as of Vesting Date of Equity Awards Granted and Vested in the Year 1,129,846 161,455 213,631 88,365 473,269 169,781 Year End Fair Value of Equity Awards Granted During the Year That are Outstanding and Unvested at Fiscal Year End 18,889,848 5,447,237 1,574,220 668,705 3,778,600 1,806,424 Year over Year Change in Fair Value of Outstanding and Unvested Equity Awards 1,076,522 388,483 ( 2,816,101 ) ( 898,695 ) 5,648,095 1,584,081 Year over Year Change in Fair Value of Equity Awards Granted in Prior Years that Vested in the Year ( 55,057 ) 5,978 ( 1,593,297 ) ( 592,025 ) 1,227,335 236,341 Fair Value at the End of the Prior Year of Equity Awards that Failed to Meet Vesting Conditions in the Year — — — — — — Compensation Actually Paid 22,207,540 6,659,604 ( 1,634,263 ) ( 61,260 ) 11,624,424 4,396,738 | ||
Named Executive Officers, Footnote [Text Block] | Our PEO for each of 2022, 2021 and 2020 was Ms. Rogers . (2) Our non-PEO Named Executive Officers for 2022 were Mr. Buchanan, Mr. Davis, Mr. Klemz (effective August 15, 2022) and Mr. Ruedy, and for 2021 and 2020 were Mr. Buchanan, Mr. Davis and Mr. Ruedy. | ||
Peer Group Issuers, Footnote [Text Block] | Total shareholder return is calculated by assuming that a $100 investment was made at the close of trading on December 31, 2019 and reinvesting all dividends until the last day of each reported fiscal year. The total shareholder return of our peer group is based on the NASDAQ US Benchmark Medical Equipment Index, as used in the Company’s performance graph in our annual report. | ||
Compensation Actually Paid vs. Total Shareholder Return [Text Block] | PEO and Average Non-PEO NEO Compensation Actually Paid versus TSR (12/31/2019 Indexed to $100) | ||
Compensation Actually Paid vs. Net Income [Text Block] | PEO and Average Non-PEO NEO Compensation Actually Paid versus Net Loss | ||
Compensation Actually Paid vs. Company Selected Measure [Text Block] | |||
Tabular List [Table Text Block] | Most Important Performance Measures Revenue Gross Margin Operating Expense | ||
Deduction For "Stock Awards" And "Option Awards" Amounts Reported In The Summary Compensation Table [Member] | |||
Pay vs Performance Disclosure [Line Items] | |||
Adjustment to Compensation Amount | $ (14,110,692) | $ (2,328,629) | $ (1,660,655) |
PEO [Member] | Fair Value As Of Vesting Date Of Equity Awards Granted And Vested In The Year [Member] | |||
Pay vs Performance Disclosure [Line Items] | |||
Adjustment to Compensation Amount | 1,129,846 | 213,631 | 473,269 |
PEO [Member] | Year End Fair Value Of Equity Awards Granted During The Year That Are Outstanding And Unvested At Fiscal Year End [Member] | |||
Pay vs Performance Disclosure [Line Items] | |||
Adjustment to Compensation Amount | 18,889,848 | 1,574,220 | 3,778,600 |
PEO [Member] | Year Over Year Change In Fair Value Of Outstanding And Unvested Equity Awards [Member] | |||
Pay vs Performance Disclosure [Line Items] | |||
Adjustment to Compensation Amount | 1,076,522 | (2,816,101) | 5,648,095 |
PEO [Member] | Year Over Year Change In Fair Value Of Equity Awards Granted In Prior Years That Vested In The Year [Member] | |||
Pay vs Performance Disclosure [Line Items] | |||
Adjustment to Compensation Amount | (55,057) | (1,593,297) | 1,227,335 |
Non-PEO NEO [Member] | Deduction For "Stock Awards" And "Option Awards" Amounts Reported In The Summary Compensation Table [Member] | |||
Pay vs Performance Disclosure [Line Items] | |||
Adjustment to Compensation Amount | (4,677,208) | (1,629,315) | (1,603,546) |
Non-PEO NEO [Member] | Fair Value As Of Vesting Date Of Equity Awards Granted And Vested In The Year [Member] | |||
Pay vs Performance Disclosure [Line Items] | |||
Adjustment to Compensation Amount | 161,455 | 88,365 | 169,781 |
Non-PEO NEO [Member] | Year End Fair Value Of Equity Awards Granted During The Year That Are Outstanding And Unvested At Fiscal Year End [Member] | |||
Pay vs Performance Disclosure [Line Items] | |||
Adjustment to Compensation Amount | 5,447,237 | 668,705 | 1,806,424 |
Non-PEO NEO [Member] | Year Over Year Change In Fair Value Of Outstanding And Unvested Equity Awards [Member] | |||
Pay vs Performance Disclosure [Line Items] | |||
Adjustment to Compensation Amount | 388,483 | (898,695) | 1,584,081 |
Non-PEO NEO [Member] | Year Over Year Change In Fair Value Of Equity Awards Granted In Prior Years That Vested In The Year [Member] | |||
Pay vs Performance Disclosure [Line Items] | |||
Adjustment to Compensation Amount | $ 5,978 | $ (592,025) | $ 236,341 |
Uncategorized Items - silk-2022
Label | Element | Value |
Measure [Axis]: 3 | ||
Measure Name | ecd_MeasureName | Operating Expense |
Measure [Axis]: 1 | ||
Measure Name | ecd_MeasureName | Revenue |
Measure [Axis]: 2 | ||
Measure Name | ecd_MeasureName | Gross Margin |